# Biotech Daily Digest — 2026-01-12

**28 items from 3 sources**

## Summary by Source

- Endpoints News: 5 items
- Fierce Biotech: 7 items
- arXiv q-bio: 16 items


## Endpoints News

- **[FDA again rejects Atara, Pierre Fabre's cell therapy for Epstein-Barr virus](https://endpoints.news/fda-again-rejects-atara-pierre-fabres-cell-therapy-for-epstein-barr-virus/)**  
  _Mon, 12 Jan 2026 13:59:22 +0000_  
  The FDA has once again rejected a T cell therapy for a rare and serious transplant complication related to Epstein-Barr virus.

 Atara Biotherapeutics' treatment, called tabelecleucel or tab-cel, is designed to treat patients with Epstein ...

- **[Arkin Capital raises $100M to back a dozen early-stage biotechs](https://endpoints.news/arkin-capital-raises-100m-to-back-a-dozen-early-stage-biotechs/)**  
  _Mon, 12 Jan 2026 13:00:45 +0000_  
  Arkin Capital has landed $100 million for its third early-stage biotech investment fund, which will support 10 to 12 drug development startups.

 The Israel-based investment firm, which backs mainly US-based biotechs, said Monday that it ...

- **[#JPM26: Moderna CEO Bancel talks deals, flu and RSV strategy](https://endpoints.news/moderna-ceo-bancel-talks-deals-flu-and-rsv-strategy/)**  
  _Mon, 12 Jan 2026 12:00:35 +0000_  
  Moderna CEO Stéphane Bancel suggested in an interview that his deals team has had a busy start to the year, as the once-celebrated vaccine maker looks to expand its business and overcome mounting US scrutiny ...

- **[Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s](https://endpoints.news/novartis-scineuro-to-work-together-on-preclinical-amyloid-targeting-drug-for-alzheimers/)**  
  _Mon, 12 Jan 2026 11:56:20 +0000_  
  Novartis is spending $165 million upfront to license a preclinical amyloid-targeting program for Alzheimer’s disease from SciNeuro.

 The companies will jointly advance the program through early development, with the Swiss drugmaker set to take over ...

- **[Signal Pulse Poll: What's the mood going into JPM?](https://endpoints.news/daily-pulse-poll/)**  
  _Sun, 11 Jan 2026 17:20:18 +0000_  
  It’s that time of year again, when deal chatter ramps up, optimism and skepticism collide, and the biopharma industry sets its New Year resolutions around the JP Morgan healthcare conference in San Francisco.

 Endpoints is ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/boston-scientific-snaps-valencia-technologies-bolster-urology-offering" hreflang="en">Boston Scientific snaps up Valencia Technologies to bolster urology offerings</a>](https://www.fiercebiotech.com/medtech/boston-scientific-snaps-valencia-technologies-bolster-urology-offering)**  
  _Jan 12, 2026 7:24am_  
  Boston Scientific is buying up privately owned medtech Valencia Technologies for its implantable device aimed at helping reduce the effects of overactive bladder disorder.

- **[<a href="https://www.fiercebiotech.com/clinical-data/novartis-pays-scineuro-165m-ticket-another-shuttle-brain" hreflang="en">Novartis pays SciNeuro $165M for ticket on another shuttle to brain</a>](https://www.fiercebiotech.com/clinical-data/novartis-pays-scineuro-165m-ticket-another-shuttle-brain)**  
  _Jan 12, 2026 8:13am_  
  Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro Pharmaceuticals.

- **[<a href="https://www.fiercebiotech.com/biotech/lynk-makes-play-jak-pot-phase-3-rheumatoid-arthritis-win" hreflang="en">Lynk makes play for the JAK pot with phase 3 rheumatoid arthritis win in China</a>](https://www.fiercebiotech.com/biotech/lynk-makes-play-jak-pot-phase-3-rheumatoid-arthritis-win)**  
  _Jan 12, 2026 8:46am_  
  A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor has hit its primary endpoint, boosting the prospects of a candidate designed to avoid the adverse events caused by existing drugs.

- **[<a href="https://www.fiercebiotech.com/sponsored/quest-diagnostics-highlights-role-vitro-diagnostics-precision-medicine" hreflang="en">Quest Diagnostics highlights role of in vitro diagnostics in precision medicine</a>](https://www.fiercebiotech.com/sponsored/quest-diagnostics-highlights-role-vitro-diagnostics-precision-medicine)**  
  _Nov 19, 2025 9:58am_  
  Quest Diagnostics emphases the critical role of in vitro diagnostics (IVDs) in shaping modern healthcare and advancing precision medicine.

- **[<a href="https://www.fiercebiotech.com/sponsored/servier-sharpens-its-focus-rare-neurology" hreflang="en">Servier Sharpens Its Focus on Rare Neurology</a>](https://www.fiercebiotech.com/sponsored/servier-sharpens-its-focus-rare-neurology)**  
  _Jan 7, 2026 11:41am_  
  Servier is committing to rare neurology for the long term, using focused science and strategic collaborations to bring new options to patients in need

- **[<a href="https://www.fiercebiotech.com/biotech/undoing-scientific-method-flagship-ceo-warns-trump-administration-dismantling-foundation-us" hreflang="en">'An undoing of the scientific method': Flagship CEO warns of government threats to US biotech industry</a>](https://www.fiercebiotech.com/biotech/undoing-scientific-method-flagship-ceo-warns-trump-administration-dismantling-foundation-us)**  
  _Jan 9, 2026 2:47pm_  
  The Trump administration spent 2025 taking a sledgehammer to science, obliterating funding and reshaping agencies like the FDA and the National Institutes of Health through layoffs and restrictive new policies. In a new letter, Noubar Afeyan, Ph.D., co-founder of Moderna and CEO of Flagship Pioneering, warns that thes…

- **[<a href="https://www.fiercebiotech.com/biotech/eikon-next-line-ipo-funds-set-bankroll-clutch-clinical-cancer-drugs" hreflang="en">Eikon next in line for IPO, with funds set to bankroll clutch of clinical cancer drugs</a>](https://www.fiercebiotech.com/biotech/eikon-next-line-ipo-funds-set-bankroll-clutch-clinical-cancer-drugs)**  
  _Jan 12, 2026 4:41am_  
  Eikon Therapeutics is planning to become the second biotech to go public in 2026 in another sign that the public markets are looking increasingly attractive to drug developers.


## arXiv q-bio

- **[Irreversible behavior drives neural flows in the hippocampus](https://arxiv.org/abs/2601.05284)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05284v1 Announce Type: new 
Abstract: In the brain, neural activity undergoes directed flows between states, thus breaking time-reversal symmetry. At the same time, animals also exhibit irreversible flows between behavioral states. Yet it remains unclear whether -- and how -- irreversibility in the brain re…

- **[Is E. coli good at chemotaxis?](https://arxiv.org/abs/2601.05301)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05301v1 Announce Type: new 
Abstract: Bacteria seem masters of chemotaxis, yet recent work suggests otherwise. Hudson Mattingly and colleagues (Nature Physics, 2026) argue that Escherichia coli uses only a small fraction of the sensory information available at its surface, challenging the long-held view tha…

- **[The rights and wrongs of rescaling in population genetics simulations](https://arxiv.org/abs/2601.05367)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05367v1 Announce Type: new 
Abstract: Computer simulations of complex population genetic models are an essential tool for making sense of the large-scale datasets of multiple genome sequences from a single species that are becoming increasingly available. A widely used approach for reducing computing time i…

- **[DNATokenizer: A GPU-First Byte-to-Identifier Tokenizer for High-Throughput DNA Language Models](https://arxiv.org/abs/2601.05531)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05531v1 Announce Type: new 
Abstract: Tokenization sits at the boundary between high-throughput genomic input and GPU compute, posing challenges in both algorithm design and system throughput. Overlapping k-mer tokenization can introduce information leakage under masked language modeling (MLM) and may degra…

- **[AntibodyDesignBFN: High-Fidelity Fixed-Backbone Antibody Design via Discrete Bayesian Flow Networks](https://arxiv.org/abs/2601.05605)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05605v1 Announce Type: new 
Abstract: The computational design of antibodies with high specificity and affinity is a cornerstone of modern therapeutic development. While deep generative models, particularly Denoising Diffusion Probabilistic Models (DDPMs), have demonstrated the ability to generate realistic…

- **[Open World Knowledge Aided Single-Cell Foundation Model with Robust Cross-Modal Cell-Language Pre-training](https://arxiv.org/abs/2601.05648)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05648v1 Announce Type: new 
Abstract: Recent advancements in single-cell multi-omics, particularly RNA-seq, have provided profound insights into cellular heterogeneity and gene regulation. While pre-trained language model (PLM) paradigm based single-cell foundation models have shown promise, they remain con…

- **[An outlook on extracellular waveforms produced by the three neuronal compartments](https://arxiv.org/abs/2601.05893)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05893v1 Announce Type: new 
Abstract: The brain is composed of billions of neurons with virtually endless morphologies and ion channel compositions, resulting in unique extracellular waveforms. Nevertheless, almost all neuronal morphologies can be reduced to a simple architecture made of three principal com…

- **[Evaluating infectious disease forecasts in a cost-loss situation](https://arxiv.org/abs/2601.05921)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05921v1 Announce Type: new 
Abstract: In order for epidemiological forecasts to be useful for decision-makers the forecasts need to be properly validated and evaluated. Although several metrics fore evaluation have been proposed and used none of them account for the potential costs and losses that the decis…

- **[On the dynamical stability of skeletal muscle](https://arxiv.org/abs/2601.05275)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05275v1 Announce Type: cross 
Abstract: There has been debate for over 70-years about whether active skeletal muscle is dynamically stable at lengths greater than its optimal length. The stability of computational muscle models is a critical issue, as it directly affects our ability to simulate muscle defor…

- **[PRISM: Protocol Refinement through Intelligent Simulation Modeling](https://arxiv.org/abs/2601.05356)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05356v1 Announce Type: cross 
Abstract: Automating experimental protocol design and execution remains as a fundamental bottleneck in realizing self-driving laboratories. We introduce PRISM (Protocol Refinement through Intelligent Simulation Modeling), a framework that automates the design, validation, and e…

- **[Tensor-DTI: Enhancing Biomolecular Interaction Prediction with Contrastive Embedding Learning](https://arxiv.org/abs/2601.05792)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05792v1 Announce Type: cross 
Abstract: Accurate drug-target interaction (DTI) prediction is essential for computational drug discovery, yet existing models often rely on single-modality predefined molecular descriptors or sequence-based embeddings with limited representativeness. We propose Tensor-DTI, a c…

- **[A latent factor approach to hyperspectral time series data for multivariate genomic prediction of grain yield in wheat](https://arxiv.org/abs/2601.05842)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05842v1 Announce Type: cross 
Abstract: High-dimensional time series phenotypic data is becoming increasingly common within plant breeding programmes. However, analysing and integrating such data for genetic analysis and genomic prediction remains difficult. Here we show how factor analysis with Procrustes…

- **[Cedalion Tutorial: A Python-based framework for comprehensive analysis of multimodal fNIRS & DOT from the lab to the everyday world](https://arxiv.org/abs/2601.05923)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2601.05923v1 Announce Type: cross 
Abstract: Functional near-infrared spectroscopy (fNIRS) and diffuse optical tomography (DOT) are rapidly evolving toward wearable, multimodal, and data-driven, AI-supported neuroimaging in the everyday world. However, current analytical tools are fragmented across platforms, li…

- **[Benchmarking LLM-based Agents for Single-cell Omics Analysis](https://arxiv.org/abs/2508.13201)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2508.13201v2 Announce Type: replace 
Abstract: The surge in multimodal single-cell omics data exposes limitations in traditional, manually defined analysis workflows. AI agents offer a paradigm shift, enabling adaptive planning, executable code generation, traceable decisions, and real-time knowledge fusion. How…

- **[A Sensitivity Analysis Methodology for Rule-Based Stochastic Chemical Systems](https://arxiv.org/abs/2509.17594)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2509.17594v3 Announce Type: replace 
Abstract: In this study, we introduce a sensitivity analysis methodology for stochastic systems in chemistry, where dynamics are often governed by random processes. Our approach is based on gradient estimation via finite differences, averaging simulation outcomes, and analyzi…

- **[Mathematical Analysis of the role of Information on the Dynamics of Typhoid Fever](https://arxiv.org/abs/2310.09825)**  
  _Mon, 12 Jan 2026 00:00:00 -0500_  
  arXiv:2310.09825v2 Announce Type: replace-cross 
Abstract: This study presents a deterministic model to examine how information affects the spread of Typhoid Fever. The models properties, including its stability and basic reproduction number, are analyzed. Simulations show that information can influence behavior in wa…
